2 Feb 2022
2 Feb 2022
UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years
Read More
1 Feb 2022
UCB Commences Tender Offer to Acquire Zogenix, Inc.
Read More
28 Jan 2022
24 Jan 2022
BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma
Read More
21 Jan 2022
